NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
AC Immune SA ACIU
11 fiscal years on record · CHF · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
CHF 3.6M
▼ 86.9% vs FY2024
EPS · FY25
CHF -0.70
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-1971.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CHF 3.6M
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 1972 cents on every revenue dollar this year.
Per share
CHF -0.70
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-1940.1%
Net margin-1971.6%
Return on assets-36.6%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−25.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−3.2%
−25.4%
−21.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CHF 154.3M
total assets, end of FY2025
Total assetsCHF 154.3M
CashCHF 26.8M
Current ratio1.02×
History
11 fiscal years
Every figure from documents filed with the SEC · CHF
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue CHF B
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.0
0.0
Operating income CHF B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
0.0
−0.0
−0.0
−0.0
0.0
EBITDA CHF B
·
·
·
·
·
·
·
·
·
·
·
Income tax CHF B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income CHF B
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
0.0
−0.1
−0.0
−0.0
0.0
EPS, diluted CHF
−0.70
−0.51
−0.64
−0.85
−0.97
−0.86
0.64
−0.82
−0.46
−0.14
0.44
Dividend / sh CHF
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
31 of 31
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed